iRhythm announces results from AMALFI clinical trial

iRhythm (IRTC) Technologies announced results from the Oxford University-led Active Monitoring for AtriaL FIbrillation, AMALFI, randomized clinical trial, presented at the European Society of Cardiology, ESC, Congress 2025 and simultaneously published in the Journal of the American Medical Association, JAMA, demonstrating that home-based screening with the Zio long-term continuous monitoring, LTCM, service led to increased atrial fibrillation detection and a shorter time to diagnosis. At 2.5 years of follow-up, the study found that home-based screening with the Zio LTCM service led to a modestly higher increase in new diagnosis of AFib in 172/2520 participants in the intervention arm vs 136/2520 participants in the control arm, and a faster time to diagnosis with AFib recorded at a median of 103 days in the intervention arm vs 530 days in the control arm, using an intention to screen analytic approach. Participants in the intervention arm were more likely to be prescribed oral anticoagulation for stroke prevention, with an average of 1.63 months exposure compared to 1.14 months in the control arm over the study period.